Target Selection for Magnetic Resonance-Guided Focused Ultrasound in the Treatment of Parkinson's Disease.
Xiaoyu WangYongqin XiongJiaji LinXin LouPublished in: Journal of magnetic resonance imaging : JMRI (2022)
Parkinson's disease (PD) is a common, progressive, and incurable neurodegenerative disease. Pharmacological treatment is the first-line therapy for PD, including carbidopa-levodopa, dopamine agonists. However, some patients respond poorly to medication. For these patients, functional neurosurgical treatment is an important option. Magnetic resonance-guided focused ultrasound (MRgFUS) is a novel, minimally invasive surgical option for patients refractory to drugs. Currently, several important anatomical structures can be targeted by MRgFUS in the treatment of PD. However, there is no uniform standard for target selection. This review summarizes the clinical studies on MRgFUS for PD, focusing on the relationship between different treatment targets and the relieved symptoms, to help clinicians determine the ideal therapeutic target for individual patients. EVIDENCE LEVEL: 5 TECHNICAL EFFICACY: Stage 4.
Keyphrases
- end stage renal disease
- magnetic resonance
- newly diagnosed
- ejection fraction
- chronic kidney disease
- healthcare
- prognostic factors
- peritoneal dialysis
- emergency department
- multiple sclerosis
- computed tomography
- magnetic resonance imaging
- drug delivery
- palliative care
- cancer therapy
- parkinson disease
- replacement therapy